GSK3B and Alzheimer disease: Moreover, the APP expression level in the treatment group significantly decreased compared with that in the model group (p < 0.05); the expression of GSK3β in the treatment group had a downward trend, but it was not statistically significant, which indicated that Formula 9002A could effectively reduce the accumulation of APP and GSK3β and delay the development of AD.